FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average t	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fitzgerald Thomas A				2. Issuer Name and Ticker or Trading Symbol  Transcode Therapeutics, Inc. [ RNAZ ]										tionship of all applic	,				
(Last) (First) (Middle) C/O TRANSCODE THERAPEUTICS, INC. 6 LIBERTY SQUARE, #2382				3. Date of Earliest Transaction (Month/Day/Year) 02/01/2022									X Officer (give title Other (specify below)  Chief Financial Officer					pecify	
(Street) BOSTON		tate)	02109 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Liı	ne) X	Form filed by More than One Reporting Person						
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)  3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)		ed (A) or	or 5. Amou		nt of s ally ollowing	Form (D) or	Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
Table II - Derivati								uired, Dis				eficiall	Price Transaction(s) (Instr. 3 and 4)						
1. Title of Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		ate, Tr	ansaction of lode (Instr. Derivative (		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				Co	ode	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$2.45	02/01/2022			A		33,000		(1)	0	1/31/2031	Common Stock	33,000		\$0	33,000	)	D	

## **Explanation of Responses:**

1. Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.

/s/ Thomas A. Fitzgerald

02/03/2022 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.